← All trials
NCT06246513
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Nov 30, 2029
- First posted
- Feb 7, 2024
- Last posted
- May 29, 2024
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sarepta TherapeuticsLead sponsor
- Sarepta TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.